While the UK ProtecT trial of treatments for PSA-detected localised prostate cancer observed only 1% mortality in men with prostate cancer after a median 10-year follow-up, there were increased risks of disease progression and metastases following active monitoring [4] and impacts on urinary, sexual and bowel function from radical surgery or radiotherapy [5]. Here, KLK3 is linked to Familial prostate cancer.